Compare Caterpillar Inc (CAT) vs Moderna, Inc. (MRNA) Price & Performance

Caterpillar (CAT) trades at $931.47, down 2.2% on the day, but has gained 51% year-to-date, driven by strong earnings beats and AI-related infrastructure demand. The stock shows a bullish moving average signal but neutral overall technicals, with support near $922. Revenue reached $67.59 billion in 2025, with a net income margin of 13.33%, though valuation multiples like a P/E of 46.48 appear elevated. Recent news highlights its role in the AI data center boom, with the Power & Energy segment seeing significant backlog growth.

The outlook remains positive given analyst consensus and AI-driven tailwinds, but high valuation and exposure to economic cycles pose risks. With 55% of analysts rating it a Buy and a consensus price target of $1,030, upside potential exists, though investors should weigh margin pressures and debt levels against growth catalysts from data center and infrastructure spending.

Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.

While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.